Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Mar 18, 2019, after the close
10-K filed Mar 18, 2019, 77 days after period end · 0001628280-19-003078
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | — | $1.91M | — | — |
| Net Income | -$5.56M | -$3.09M | -$1.64M | -$3.65M |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| EPS Diluted | — | -$0.11 | -$0.18 | -$0.53 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.